格林改善了代谢综合征患者的内皮功能
Manfredi Tesauro1, Francesca Schinzari, Micaela Iantorno
1Dipartimento di Medicina Interna, Università di Tor Vergata, Rome, Italy.
Circulation
|November 2, 2005
概括
格林的使用通过增强氧化来改善代谢综合征患者的内皮功能障碍. 在这些患者中,较低的林水平可能会导致动脉样硬化的发展.
科学领域:
- 心血管科学 心血管科学
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 代谢综合征加速动脉样硬化,从内皮功能障碍开始.
- 格林是一种类激素,表现出心血管效应,并可能抑制益风原性变化.
- 这项研究探讨了格林对代谢综合征中的内皮功能的影响.
研究的目的:
- 为了研究格林在患有代谢综合征的患者内皮功能上的作用.
- 为了确定格林是否可以逆转与代谢综合征相关的内皮功能障碍.
主要方法:
- 评估了依赖内皮细胞 (乙胆) 和依赖内皮细胞 (乙胆) 和独立的 (SNP) 血管扩张反应,使用压力测量 Plethysmography.
- 在代谢综合征和对照患者的局部林输注前后测量反应.
- 测量了基底血格林水平和氧化的生物可用性.
主要成果:
- 与对照组相比,代谢综合征患者的乙胆血管扩展剂反应减弱.
- 代谢综合征患者的基础血格林水平较低.
- 在代谢综合征患者中,格林注增强了乙胆反应,表明内皮功能得到改善.
- 这种改善与增强的氧化生物可用性有关.
结论:
- 格林林的使用通过增加氧化的生物活性来逆转代谢综合征中的内皮功能障碍.
- 循环林水平降低可能有助于这些患者动脉样硬化的病理生物学.
相关概念视频
Hormones Regulating Blood Glucose
7.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.5K
Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
751
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
751
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


